Игорь Владимирович Борисевич

Игорь Владимирович Борисевич

Auto-generated profile, based on publicly available information

Игорь Владимирович Борисевич

Federal Medical Biological Agency

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Citologiâ
Verified
Journal Article
Closed access
SFScientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of the Russian Federation
Scientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of the Russian Federation
EME.V. Melnikova
E.V. Melnikova
OMO.V. Merkulova
O.V. Merkulova
IBI.V. Borisevich
I.V. Borisevich
VMV.A. Merkulov
V.A. Merkulov
Разрабатываемые в настоящее время биомедицинские клеточные продукты (БМКП), а также продукты клеточных технологий, имеющих действующие бессрочно разрешения и лицензии на их использование, с 1 января 2017 г. регулируются Федеральным законом № 180-ФЗ от 23.06.2016 г. «О биомедицинских клеточных продуктах» и нормативно-правовыми актами, обеспечивающими его действие. Для некоторых медицинских технологий на сегодняшний день имеются положительные результаты практики клинического применения, однако правила производства, проведения доклинической оценки и клинических исследований таких препаратов до принятия № 180-ФЗ от 23.06.2016 г. не регулировались. Кроме того, для использования в практике здравоохранения БМКП должны пройти процедуру государственной регистрации. В обзоре представлены данные о типе препаратов на основе жизнеспособных клеток человека и опыте их применения до принятия № 180-ФЗ от 23.06.2016 г., а также о перспективных разработках, проводимых в Российской Федерации в области создания...

8 November 2006
Verified
Journal Article
Closed access
IBI V Borisevich
I V Borisevich
VMV A Markin
V A Markin
IFI V Firsova
I V Firsova
AEA A Evseev
A A Evseev
RKR A Khamitov
R A Khamitov
VMV A Maksimov
V A Maksimov

30 September 2008
Verified
Journal Article
Closed access
AGA A Grigor'Ev
A A Grigor'Ev
VBV P Bondarev
V P Bondarev
IBI V Borisevich
I V Borisevich
IDI V Darmov
I V Darmov
AMA V Mironin
A V Mironin
DID S Ianov
D S Ianov

1 January 2023 in Immunologiya
Verified
Journal Article
Open access
ESE.V. Shvedova
E.V. Shvedova
AKA.G. Klepikova
A.G. Klepikova
OFO.V. Fadeikina
O.V. Fadeikina
DSD.V. Shvedov
D.V. Shvedov
IBI.V. Borisevich
I.V. Borisevich
ASAlexander А. Soldatov
Alexander А. Soldatov
Разработка фармакопейного стандартного образца для количественного определения активности иммуноглобулина человека антирезус Rho(D)

6 March 2008
Verified
Journal Article
Closed access
IBI V Borisevich
I V Borisevich
NPN V Potryvaeva
N V Potryvaeva
SMS A Mel'Nikov
S A Mel'Nikov
AEA A Evseev
A A Evseev
VKV P Krasnianskiĭ
V P Krasnianskiĭ
VMV A Maksimov
V A Maksimov

13 September 2023 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
ANA. V. Nechaev
A. V. Nechaev
EKE. Yu. Kudasheva
E. Yu. Kudasheva
EPE. L. Postnova
E. L. Postnova
RVR. A. Volkova
R. A. Volkova
OFO. V. Fadeikina
O. V. Fadeikina
AMA. A. Movsesyants
A. A. Movsesyants
Scientific relevance. The immunoglobulin A (IgA) impurity content in parenteral human immunoglobulins should be determined in accordance with the State Pharmacopoeia of the Russian Federation by kinetic nephelometry, radial immunodiffusion, or enzyme immunoassay (ELISA) with a reference standard. The International Standard (IS) for the content of IgA is certified using gravimetry and radial immunodiffusion. However, neither of the existing standards for the content of IgA in human immunoglobulins is currently certified using all three compendial methods. This prevents analysts from comparing test results obtained by different methods and may lead to an underestimation of the IgA content in human immunoglobulins.Aim. This study aimed to determine the procedure for the development, certification, and use of a pharmacopoeial reference standard (RS) for the content of IgA in human immunoglobulins.Materials and methods. The authors studied candidate RSs for the IgA content derived from human plasma for fractionation. The IgA content determination involved kinetic nephelometry, radial immunodiffusion, and ELISA, as well as commercial test kits and the IS. The authors quantified the IgA impurity in samples of commercial human immunoglobulins from various manufacturers. The data analysis involved descriptive statistics and variance analysis using Microsoft Excel and Statistica 10.Results. The authors established a pharmacopoeial standard with a certified IgA content of 1.98 mg/mL (expanded uncertainty, 0.44 mg/mL; coverage coefficient, k=2; confidence level, 95%) for IgA impurity quantification in human immunoglobulins by radial immunodiffusion and ELISA and that of 1.31–2.64 mg/mL (expanded uncertainty, 0.67 mg/mL; coverage ratio, k=3; confidence level, 99%) for intralaboratory quality control of IgA impurity quantification by kinetic nephelometry, radial immunodiffusion, and ELISA.Conclusions. The pharmacopoeial standard developed in the study has been included in the register of standards of the State Pharmacopoeia of the Russian Federation as the Reference Standard for the Content of Immunoglobulin Class A (IgA) (Registry No. 3.1.00454). The pharmacopoeial standard is intended for the standardisation of analytical methods for the-determination of the IgA impurity content in parenteral human immunoglobulins.